Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer

Future Oncology

Volumn 6, Issue 1, 2010, Pages 25-35

  Bollschweiler, Elfriede ^a   Hölscher, Arnulf H ^a   Metzger, Ralf ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Adenocarcinoma; Esophagus; Neoadjuvant chemoradiation; Pathologic complete response; Regression grading; Squamous cell carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL;

CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER RADIOTHERAPY; CANCER REGRESSION; DRUG RESPONSE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; PREOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, RADIATION; ESOPHAGEAL NEOPLASMS; HUMANS; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 75149144082     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.133     Document Type: Review

References (64)

1. Mariette C, Piessen G, Triboulet JP: Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 8, 545-553 (2007).
2. Urschel J, Vasan H, Blewett C: A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am. J. Surg. 183, 274-279 (2002).
3. Kaklamanos I, Walker G, Ferry K, Franceschi D, Livingstone A: Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann. Surg. Oncol. 10, 754-761 (2003).
4. Urschel J, Vasan H: A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am. J. Surg. 185, 538-543 (2003).
5. Fiorica F, Di BD, Schepis F et al.: Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53, 925-930 (2004).
6. Greer S, Goodney P, Sutton J, Birkmeyer J: Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery 137, 172-177 (2005).
7. Kelsen D, Winter K, Gunderson L et al.: Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J. Clin. Oncol.25, 3719-3725 (2007).
8. Lordick F, Stein H, Peschel C, Siewert J: Neoadjuvant therapy for oesophagogastric cancer. Br. J. Surg. 91, 540-551 (2004).
9. Gebski V, Burmeister B, Smithers B, Foo K, Zalcberg J, Simes J: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 8, 226-234 (2007).
10. Adelstein D, Rice T, Becker M et al.: Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer 80, 1011-1020 (1997).
11. Ribeiro A, Franceschi D, Parra J et al.: Endoscopic ultrasound restaging after neoadjuvant chemotherapy in esophageal cancer. Am. J. Gastroenterol. 101, 1216-1221 (2006).
12. Bates B, Detterbeck F, Bernard S, Qaqish B, Tepper J: Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J. Clin. Oncol.14, 156-163 (1996).
13. Brown W, Thomas J, Gotley D et al.: Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br. J. Surg. 91, 199-204 (2004).
14. Schneider P, Metzger R, Schaefer H et al.: Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann. Surg. 248, 902-908 (2008).
15. Sarkaria I, Rizk N, Bains M et al.: Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann. Surg. 249, 764-767 (2009).
16. Hermann R, Krech R, Hartlapp J et al.: [The value of qualitative regression grading as a prognostic factor for survival after preoperative radiochemotherapy in patients with advanced head and neck cancer]. Strahlenther. Onkol. 177, 277-282 (2001).
17. Miller A, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47, 207-214 (1981).
18. Therasse P, Arbuck S, Eisenhauer E et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92, 205-216 (2000).
19. Mandard A, Dalibard F, Mandard J et al.: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73, 2680-2686 (1994).
20. Junker K, Langner K, Klinke F, Bosse U, Thomas M: Grading of tumor regression in non-small cell lung cancer: morphology and prognosis. Chest 120, 1584-1591 (2001).
21. Junker K, Muller K, Bosse U, Klinke F, Heinecke A, Thomas M: [Apoptosis and tumor regression in locally advanced non-small cell lung cancer with neoadjuvant therapy]. Pathologe 24, 214-219 (2003).
22. Baldus S, Monig S, Schroder W et al.: [Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation]. Pathologe 25, 421-427 (2004).
23. Schneider P, Baldus S, Metzger R et al.: Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann. Surg. 242, 684-692 (2005).
24. Shimosato Y, Oboshi S, Baba K: Histological evaluation of effects of radiotherapy and chemo-therapy for carcinomas. Jpn. J. Clin. Oncol. 1, 19-35 (1971).
25. Becker K, Mueller J, Schulmacher C et al.: Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98, 1521-1530 (2003).
26. Japanese Society for Esophageal Diseases: Guidelines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus (9th Edition). Kanehara and Co. Ltd, Tokyo, Japan (2001).
27. Yonemura Y, Kinoshita K, Fujimura T et al.: Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients. Hepatogastroenterology 43, 1260-1272 (1996).
28. Darnton S, Allen S, Edwards C, Matthews H: Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy. J. Clin. Pathol. 46, 51-55 (1993).
29. Schneider S, Uchida K, Brabender J et al.: Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J. Am. Coll. Surg. 200, 336-344 (2005).
30. Wu T, Chirieac L, Abraham S et al.: Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am. J. Surg. Pathol. 31, 58-64 (2007).
31. Chang E, Smith C, Corless C, Thomas C, Hunter J, Jobe B: Accuracy of pathologic examination in detection of complete response after chemoradiation for esophageal cancer. Am. J. Surg. 193, 614-617; discussion 617 (2007).
32. Sielezneff I, Thomas P, Giovannini M, Giudicelli R, Seitz JF, Fuentes P: Esophageal-carcinoma with doubtful extirpability - value of preoperative chemotherapy plus radiotherapy. Eur. J. Cardiothorac. Surg. 7, 606-611 (1993).
33. Apinop C, Puttisak P, Preecha N: A prospective-study of combined therapy in esophageal cancer. Hepatogastroenterology 41, 391-393 (1994).
34. Leprise E, Etienne PL, Meunier B et al.: A randomized study of chemotherapy, radiation-therapy, and surgery versus surgery for localized squamous-cell carcinoma of the esophagus. Cancer 73, 1779-1784 (1994).
35. Malhaire JP, Labat JP, Lozach P et al.: Preoperative concomitant radiochemotherapy in squamous cell carcinoma of the esophagus: results of a study of 56 patients. Int. J. Radiat. Oncol. Biol. Phys. 34, 429-437 (1996).
36. Bosset JF, Gignoux M, Triboulet JP et al.: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N. Engl. J. Med. 337, 161-167 (1997).
37. Ganem G, Dubray B, Raoul Y et al.: Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the esophagus. J. Clin. Oncol. 15, 701-711 (1997).
38. Adham M, Baulieux J, Mornex F et al.: Combined chemotherapy and radiotherapy followed by surgery in the treatment of patients with squamous cell carcinoma of the esophagus - the Croix Rousse experiences. Cancer 89, 946-954 (2000).
39. Urba S, Orringer M, Turrisi A, Iannettoni M, Forastiere A, Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J. Clin. Oncol.19, 305-313 (2001).
40. Burmeister BH, Smithers BM, Gebski V et al.; Trans Tasman Oncology G, Australasian Gastro Trials G: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled Phase III trial. Lancet Oncol. 6, 659-668 (2005).
41. Rohatgi P, Swisher S, Correa A et al.: Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer 106, 552-558 (2006).
42. Mariette C, Piessen G, Lamblin A, Mirabel X, Adenis A, Triboulet J: Impact of preoperative radiochemotherapy on postoperative course and survival in patients with locally advanced squamous cell oesophageal carcinoma. Br. J. Surg. 93, 1077-1083 (2006).
43. Bedenne L, Michel P, Bouche O et al.: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J. Clin. Oncol. 25, 1160-1168 (2007).
44. Reynolds J, Muldoon C, Hollywood D et al.: Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann. Surg. 245, 707-716 (2007).
45. Barbour A, Jones M, Gonen M et al.: Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Ann. Surg. Oncol. 15, 2894-2902 (2008).
46. Akutsu Y, Matsubara H, Shuto K et al.: Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients. World J. Surg. 33, 1002-1009 (2009).
47. Bollschweiler E, Metzger R, Drebber U et al.: Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann. Oncol. 20, 231-238 (2009).
48. Urba S, Orringer M, Perez-Tamayo C, Bromberg J, Forastiere A: Concurrent preoperative chemotherapy and radiation therapy in localized esophageal adenocarcinoma. Cancer 69, 285-291 (1992).
49. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N. Engl. J. Med. 335, 462-467 (1996).
50. Wright C, Wain J, Lynch T et al.: Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a Phase I and II study. J. Thorac. Cardiovasc. Surg. 114, 811-815; discussion 816 (1997).
51. Keller SM, Ryan LM, Coia LR et al.: High dose chemoradiotherapy followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction - results of a Phase II study of the Eastern Cooperative Oncology Group. Cancer 83, 1908-1916 (1998).
52. Ajani JA, Komaki R, Putnam JB et al.: A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 92, 279-286 (2001).
53. Henry L, Goldberg M, Scott W et al.: Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a Phase II report. Ann. Surg. Oncol. 13, 214-220 (2006).
54. Lowy A, Firdaus I, Roychowdhury D et al.: A Phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma. Am. J. Clin. Oncol. 29, 555-561 (2006).
55. Luu T, Gaur P, Force S et al.: Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer. Ann. Thorac. Surg. 85, 1217-1223; discussion 1223-1224 (2008).
56. Tepper J, Krasna M, Niedzwiecki D et al.: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J. Clin. Oncol. 26, 1086-1092 (2008).
57. Donahue J, Nichols F, Li Z et al.: Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann. Thorac. Surg. 87, 392-398; discussion 398-399 (2009).
58. Kesler K, Helft P, Werner E et al.: A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followed by surgery or surgery alone. Ann. Thorac. Surg. 79, 1116-1121 (2005).
59. Geh J, Bond S, Bentzen S, Glynne-Jones R: Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother. Oncol. 78, 236-244 (2006).
60. Mariette C, Piessen G, Briez N, Triboulet J: The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann. Surg. 247, 365-371 (2008).
61. Prenzel K, Konig A, Schneider P et al.: Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer. Ann. Surg. Oncol. 14, 954-959 (2007).
62. Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, Lagergren J: Survival after neoadjuvant therapy compared with surgery alone for resectable esophageal cancer in a population-based study. World J. Surg. 30, 2182-2190; discussion 2191-2192 (2006).
63. Read T, Andujar J, Caushaj P et al.: Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status. Dis. Colon Rectum 47, 825-831 (2004).
64. Metzger R, Drebber U, Baldus SE, Monig SP, Holscher AH, Bollschweiler E: Extracapsular lymph node involvement differs between squamous cell and adenocarcinoma of the esophagus. Ann. Surg. Oncol. 16, 447-453 (2009).